Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
*Will even..
Do you think there we’ll be a placing then porky?
(2)
•••
Post by Carolpeters24 on Jul 26, 2022 10:31am
ValiRx and TheoremRx - VAL201 - US$61M plus royalties
Dr Ken Sorensen, Chairman of TheoremRx We are delighted out latest fundraising od $250m has brought in multiple financial institutions as we now move forward with our strategic plans.
Dr Ken Sorensen, Chairman of TheoremRx stated: "We have appreciated the work carried out so far, and we will now move forward with VAL201 as it is an important part of our pipeline of new projects."
First payments to ValiRx are expected on or before the end of July.
The proposed sub-licence of VAL201 to TheoremRx Inc. VAL201's primary indication is for prostate cancer, with potential further research & development in breast and ovarian cancer.
The potential value of the deal would be in excess of US$61M plus royalties for the first cancer indication alone. Each oncology indication successfully developed to by TheoremRx will generate up to $37.5M of additional value to ValiRx. The proposed deal structure comprises payments on signature of the Licence Agreement plus fees and near-term milestones totalling US$2.2M before the end of 2023, milestones on further clinical and commercial development events, and royalties. The first payments are expected by the end of July 2022.
https://www.fidelity.co.uk/shares/stock-market-news/company-news/
30 day exclusivity agreement between EUDA and TRx comes to an end early next month. Should get some news then anyway, not long now! Appreciate there’s plenty of downside risk here, Porky… but fingers crossed you’re wrong. Squeaky bum time!
@IM
Not exactly, they need as much hype and pump here as possible to keep the SP at the 10p level to ensure best chance of placing at 2p to 4p this is the name of the game. Suzy needs to remain more bullish than ever otherwise she won’t get the placing away.
I have seen this kind of situation many times over the years and what is sad is that newbies get taken in by it only to lose the bulk of their investment when the placing RNS lands.
As for your key point:”It’s logical that TRX have the funds, but I don’t know” what you should be posting is that it’s totally illogical they have the funds, think about it:-
We are talking a stateside raise of at least 60-100m if they had secured that kind of cash on hold in an account somewhere do you not think the 1.3m odd would already be in VALs account? After all it’s a measly 1% odd of what they claim to have raised?
BUT moreover: again if true do you not think it would be covered by every financial paper known to man, that in a Biotech funding drought, THX have raised 100m on the Nasdaq? It’s all BS there isn’t even a link to prospectus anywhere?
Anyhow, discounted placing from VAL any moment, it’s just a case of what price they can secure.
Who created this "hype bubble"? It is pure straw-clutching to maintain that TheoremRX are going through the motions of a merger just to add a few pence onto VAL's SP. You keep implying that it's all a conspiracy.
1. The time it would take to do both a merger and then a subsequent Nasdaq listing are far far far beyond VALs current cash runway - FACT
2. Three weeks on and still no transfer of funds. IF THX had already placed as the rampers claim where is the evidence of same and where is the money?
3. Give me a link to any placing document anywhere that proves funds were raised and on hold subject to... you can’t
The harsh reality is that this two bit outfit only THINK they can raise as a new entity but there are no guarantees they can and to assume they could do that within a few weeks is pure folly.
Don’t you think it’s mighty convenient that this hype bubble has been created just before funds are about to run out so VAL can try and get the placing away? I stand by 20m at 4p to raise £800k or if Turner Pope struggle 40m at 2p to raise £800k. This amount would extend the cash runway by 3 or 4 months to allow more time.
Either way it’s Placing FIRST anything else after that/if at all.
One thing is certain: if SH get behind this placing now and THX still don’t send cash by end of Q1 2024 they will need a larger raise again pre the AGM.
Not long now, just awaiting the resolution details for the VAL discounted placing and EGM date
Good luck
@porky
Ramping this to death?
I would say my posts certainly don't fit your agenda. But, if you actually read them you would see that I have questioned working capital.
I was categorical in stating that capital is likely to be diminishing, but that H2 cash burn cannot easily be extrapolated from H1 for reasons I've previously stated.
I believe the merger will succeed, but I don't know.
It is logical that TRx have the funds, but I don't know.
I hope that the payment is received before WCap is required, but I don't know.
I do know we have doubled in price this month and you don't like it
I'm flattered my posts have recommends, but it isn't ramping. Maybe it's because it's viewed as a cogent, balanced precis of what the current situation is?
I am glad you don't like that either.
@IM
There are FIVE here including you that are ramping this to death, you have built this ridiculous Hype bubble over the last three weeks since 5p.
Your post gets a load of recs because long term holders are desperately underwater and really don’t want yet another placing when the harsh reality is it’s the ONLY realistic outcome.
None of the points you raise count for diddly squat, this is 100% a binary play: either THX transfer the cash before lights out at the turn of the year OR shareholders dig deep and invest further capital in the placing; I believe the latter. So:
THX transfer the funds now = no placing until after June 24 (THX cash would only last 6mths anyhow)
THX still don’t transfer the funds = Placing shortly plus additional one end of Q1 24 if THX still not come though with the cash.
It’s that simple
Great post. “Recommended” myself and by many others as a show of solidarity for the well reasoned thinkers who use facts and evidence to draw conclusions. Refreshing to know despite all the effort put in to deramping VAL day & night, the vast majority of the viewership on this BB agree with facts and evidence. Roll on next week.
Another superb post Ironmighty. Spot on.
“Desperate times call for desperate measures” and for the de-ramping club the time is now.
When I posted about the live TheoremRX website, the derampers were all over it. I was even accused of fabricating it.
It was then proved that the website was registered at the same time as TheoremRX was incorporated in 2020.
So, it was then stated that the website was a hoax, because it was registered at an NY residential address.
I then proved that that address is used by other companies that belong to Kenneth Sorensen, the chairman of TheoremRX.
When I found the media info about the merger, some posters were so thrown by it they screamed that the merger was a RUSE (yes, really). That it was 'fake news' to fluff up the SP for an immediate placing. Basically accusing the CEOs of two companies of being frauds. Then it became obvious it was all real news.
Some posters resorted to exclaiming that TRx have raised no money whatsoever - that a clearly struggling EUDA were going to merge with a private company that had nothing to bring whatsoever? Most realised very quickly that it made no sense.
With few moves remaining, one poster even tries to derail the merger by libelling TheoremRX on a US EUDA bb. Desperate times, desperate measures.
And now there is so little left to attack on this deal, the remaining few are only left with VAL201 itself :)
Let me guess, VAL201 is just a RUSE. Maybe it's FAKE. Maybe TheoremRX have been DUPED into taking it, spending all that time and planning to spend all that money on a drug that doesn't "bloody work"?
I've spent a lot of time on Valirx. I'd spend more to refute such claims, but the SUBLICENSING DEAL HAS ALREADY BEEN AGREED. It would be pointless.
I've spent a quarter of a century working with data and statistics. I'd spend more looking at the data again myself, but I'm certainly not going to, because the SUBLICENSING DEAL HAS ALREADY BEEN AGREED. It would also be pointless.
I wonder what's left to attack?
Enjoy your Sunday.
Ratcliffewriter - Absolutely right. Anyone asking for information that is clearly already public information must be ignored. Such as porkey9 who claims not to know where Suzy lives, but with a Google Search knows that she lives in Fxxxxxx Way, Nuneaton, England, Cxxx 6xx .
What ever it is porky has here, seem to raise a suspicion that it may well be nefarious.
You can always spot a ramping crew member by their continuous fishing for details on those who don't toe the line. What sex is nomlungu? What is RW's age? Do you own shares? Are you planning to buy? Where does P9 live?
Data is valuable and can be used, keep fishing lads, it's your best way of gaining information to attack.
Why are your crew so keen to know details that have no relevance whatsoever to any investment decisions?
Nothing wrong with being curious. Sounds like an angry woman? Are you angry in real life Nom?
Rat you come across as a old man perhaps over 85? Am I right?
Uxm - would it make a difference to your attitude if you knew? Or is your reply just an attempt at distraction from pertinent facts?
Nom,
Are you man or women?
Nomlungu, get over it ffs.
Val is progressing and the mkt cap growth will come through shortly.
Ray - the definition of non-progression is also relevant
To meet PCWG2 criteria for non-progression (stable disease), patients must observe:
• PSA increase no greater than 25%
• Tumour size increase no greater than 20%
• No more than 1 additional metastatic lesion
The full trial results are here:
https://www.valirx.com/our-pipeline/val201
To clarify, the definition of responder given as follows:
"If no progressive disease was declared at any time that the patient was on the trial, the patient is declared a responder."
* that should read ‘less risk-averse party’
Interesting seeing whose posting today. The concern over a prospectus outlining completed funding seems to have some shorters rattled.
Little point questioning the val201 clinical data. Theoremrx think it’s worth paying millions for. Yes, the sample was too small for big pharma interest, but the results were statistically significant to warrant it being licensed from a this risk-averse party. Like it or not, TheoremRx are experts and have had a lot of time for DD. They wish to include it in their suite of oncology drugs, they’re not doing it out of charity.
It's interesting, I can't get an answer to this simple question. Instead I get pointed to smart investors or companies that intend to licence is.
I suspect I would have gotten a similar response to my question from Theranos.
Share 4, in answer:
Enough patients to license it to THX for $61mn with royalties, inflection point bonuses, monthly service agreement, $2.2mn upfront and $37mn per other indications added.
LOL
Share4 don’t you think he has better things to do on Saturday night, the rugby starts soon! Go and do your own research if you’re so interested.